Next steps in the development of the memodio app and its potential role in clinical practice

Preliminary insights from a 12-week app-based intervention in patients with cognitive decline

The need for non-pharmacological treatment for dementia: introducing the memodio app

Gene therapy in dementia: what advances are being made in Alzheimer’s and frontotemporal dementia?

EEG alterations in Alzheimer's disease: which markers should clinicians be aware of?

Managing hyperexcitability in AD: should antiseizure medication be used?

The connection between Alzheimer's disease and hyperexcitability observed on EEG

What are the next steps in the field of blood-based biomarkers for AD?

Reflecting on the recent FDA approval of the first blood-based diagnostic test for AD

The two cut-offs approach for plasma p-tau217 to detect AD in a real-world population

Advancing anti-amyloid antibody therapies in AD: future directions and improving access

Barriers and solutions for initiating anti-amyloid therapies for Alzheimer's disease

Coordination of clinical, imaging, and infusion services to manage anti-amyloid therapy for AD

The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes

The clinical experience with lecanemab therapy in patients with MCI and early-stage AD

The complexity of vaccine development for neurodegenerative diseases

The future of immunotherapeutic approaches for the treatment of neurodegenerative diseases

Promising vaccine targets for alpha-synucleinopathies

Exploring a vaccine-based approach to targeting Aβ oligomers in Alzheimer’s disease

Advancing frontotemporal dementia diagnosis through biomarkers and imaging

From mutation to meaning: revisiting the PSEN1 Alzheimer’s story

Real-world outcomes with lecanemab in early Alzheimer's disease

The future of biomarkers in dementia diagnosis and the role of tau-PET imaging

The future of AI in neurology

AI in neurology: evaluation and clinical implementation

The development of a multi-modal AI framework for differential diagnosis of dementia

Using AI to improve clinical trial screening in neurology

The importance of harmonizing tau-PET tracers in AD research and clinical practice

The new Alzheimer's Association work group criteria for staging AD

Early recognition and specialist referral critical for Alzheimer's intervention

Advances and challenges in diagnosing Alzheimer's and associated disorders

Updated Alzheimer's Association clinical practice guidelines for diagnosing AD and related disorders

Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab

Recommendations for the appropriate use of donanemab in Alzheimer’s disease

Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease

Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease

The development of lecanemab for the treatment of early Alzheimer’s disease

Measuring clinically relevant change in apathy symptoms in AD using data from the ADMET trials

A study investigating nabilone for the treatment of agitation in AD

The value and limitations of p-tau217 in AD clinical trials

Advances in fluid biomarker research for the treatment of neurodegenerative diseases

Comparing different assays for detecting AD plasma biomarkers

CS6253: a novel peptide with the potential to lower the risk of Alzheimer’s disease

PreventE4: evaluating the role of omega-3 in cognitive health and Alzheimer’s disease

The great debate: defining AD beyond amyloid-β

Novel therapeutics being explored in AD and moving towards combination approaches

Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment

Understanding agitation in Alzheimer’s disease and current approaches to management

Lecanemab: slowing the progression of AD and the potential for subcutaneous administration

Using a p-tau217 assay to screen participants for the ALTITUDE-AD trial

The ALTITUDE-AD trial: targeting soluble amyloid-β oligomers with sabirnetug in AD

The potential of targeting omega-3 metabolism in the brain to prevent AD

The International Working Group’s new recommendations for diagnosing AD

A Phase II trial of nilotinib in patients with dementia with Lewy bodies

An automated speech tool to screen for cognitive impairment: a study in four European cohorts

The need for digital tools to assess cognition in Alzheimer's disease

Using blood testing to improve the accuracy of AD diagnosis in primary and secondary care settings

Comparing plasma ptau217 with CSF biomarkers for predicting tau PET status

The accuracy of plasma tau217 biomarkers in detecting AD pathology

Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials